If I am not willing to hold [ENTA] into the Abbvie launch…it is safe to conclude that I am not willing to hold it for the NVS partnership.
The difference is that the NVS partnership is almost “pure” upside for ENTA if anything of consequence should happen this year. Nobody is modeling much, if any, value for this program.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”